Laura Chong, MD
Allergy & Immunology · Oklahoma City, OKNPI 1174581508
Payments from drug & device makers
Across 451 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$883
- GSK$734
- CSL Behring$705
- Regeneron Healthcare Solutions, Inc.$687
- Genentech USA, Inc.$669
- plus $4K from 27 others
What the payments were for
- Travel & lodging$20%
- Food & beverage$8,76099%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,217 |
| Sanofi | 40 | $883 |
| GSK | 65 | $734 |
| CSL Behring | 33 | $705 |
| Regeneron Healthcare Solutions, Inc. | 37 | $687 |
| Genentech USA, Inc. | 25 | $669 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $589 |
| Amgen | 32 | $556 |
| Novartis | 29 | $543 |
| Blueprint Medicines Corporation | 13 | $354 |
| Optinose US, Inc. | 20 | $319 |
| Pfizer | 13 | $291 |
| Grifols USA, LLC | 9 | $183 |
| Kaleo, Inc. | 8 | $162 |
| Pharming Healthcare, Inc. | 6 | $139 |
| Alk-abello, Inc | 6 | $134 |
| Aimmune Therapeutics, Inc. | 6 | $98 |
| Biocryst US Sales Co., LLC | 5 | $89 |
| AbbVie | 3 | $77 |
| Hikma Pharmaceuticals USA | 3 | $62 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $59 |
| Shire North American Group Inc | 2 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Genentech, Inc. | 1 | $35 |
| Galderma Laboratories, L.p. | 1 | $30 |
| Dermavant Sciences, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| LEO Pharma Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Organon | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 26 | $97,070 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $79,724 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $48,640 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $48,041 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $32,692 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $28,040 |
| Epinephrine | 126 | $23,829 |
| Spiriva RespimatTiotropium Bromide | 31 | $16,301 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $11,353 |
| DuleraMometasone/Formoterol | 25 | $10,554 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $8,472 |
| Montelukast Sodium | 386 | $7,757 |
| Ipratropium Bromide | 174 | $5,935 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $5,768 |
| Levocetirizine Dihydrochloride | 210 | $5,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $734 | $111,726180 claims |
| CSL BehringPrivigen | $705 | $48,64013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $589 | $48,04120 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,217 | $41,16466 claims |
| Hikma Pharmaceuticals USAEpinephrine | $62 | $23,829126 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $36 | $5,76817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Oklahoma City
- Amy DarterOklahoma City$559K
- Shahan StutesOklahoma City$43K
- Dean AtkinsonOklahoma City$13K
- Richard HatchOklahoma City$8K
- Patricia OverhulserOklahoma City$6K
- Warren FilleyOklahoma City$345
- Iftikhar HussainTulsa$7.1M
- Bret HaymoreBroken Arrow$368K
- Nalin UgEdmond$93K
- Weyman LamTulsa$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.